Radiation and concomitant weekly administration of paclitaxel in patients with glioblastoma multiforme. A phase II study

Journal of Neuro-Oncology

Volumn 45, Issue 2, 1999, Pages 159-165

  Fountzilas, George ^a   Karavelis, Antonios ^a   Capizzello, Antonio ^a   Kalogera Fountzila, Anna ^a   Karkavelas, George ^a   Zamboglou, Nikolaos ^b   Selviaridis, Panayiotis ^a   Foroglou, George ^a   Tourkantonis, Achilles ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Stadische Kliniken   (Germany)

Author keywords

Brain tumors; Chemotherapy; Paclitaxel; Radiotherapy

Indexed keywords

PACLITAXEL;

ADULT; ALOPECIA; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; INFECTION; MALE; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RADIATION DOSE; RISK ASSESSMENT; TOXICITY TESTING; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; RADIOTHERAPY; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0033513280     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006386114104     Document Type: Article

References (31)

1. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasm. Neurology 35: 219, 1985
2. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. CA Cancer J Clin 44: 7-26, 1994
3. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993
4. Cahan MA, Walter KA, Colvin OM, Brem H: Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chem Pharm 33: 441-444, 1994
5. Helson L, Helson C, Malik S, Ainsworth S, Mangiardi J: A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anti, Cane Drug 4:487-490, 1993
6. Hei TK, Piao CQ, Geard CR, Hall EJ: Taxol and ionising radiation: interaction and mechanisms. Int J Radiation Oncol Biol Phys 29: 267-271, 1994
7. Geard CR, Jones JM, Schiff PB: Taxol and radiation. Monogr Natl Cancer Inst 15: 89-94, 1993
8. Nitta T, Sato K: Prognostic implication of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 75: 2727-2731, 1995
9. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 56: 1106-1111, 1985
10. MacDonald DR, Cascino TL, Schold SCJ, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Neurosurg 8: 1277-1280, 1990
11. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB: Modified procarbazine, CCNU and vincristine (PCV-3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64: 237-241, 1980
12. Soini Y, Niemela A, Kamel D, Herva R, Bloigu R, Paakko P, Vahakangas K: p53 immunohistochemical positivity as a prognostic marker in intracranial tumors. APMIS 102: 786-792, 1994
13. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
14. Mantel M: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966
15. Yokes EE, Pajak TF: Enhancing the therapeutic index of concomitant chemoradiotherapy for head and neck cancer. Ann Oncol 9: 471-473, 1998
16. Choy H, Akerley W, Safran H, Clark J, Rege V, Papa A, Glantz M, Puthawala Y, Soderberg C, Leone L: Phase I study trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small cell lung cancer. J Clin Oncol 12: 2682-2686, 1994
17. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Kuhn J, Lamborn K, Rector DJ, Chang SM: Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14: 2316-2321, 1996
18. Chamberlain MC, Kormanik P: Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066-2071, 1995
19. Chang SM, Kuhn JG, Rizzo J, Robins HI, Schold C Jr, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Gilbert M, Fulton D, Rankin C, Malec M, Prados M: Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J Clin Oncol 16: 2188-2194, 1998
20. Briasoulis E, Tzamakou E, Nicolaides C, Karavasilis V, Pavlidis N: Long-term weekly administration of paclitaxel in chemotherapy-naive patients, phase I study: single versus cumulative dose limiting toxicity (Abstr). Proc Am Soc Clin Oncol 16: 812, 1997
21. Glantz MJ, Choy H, Kearns CM, Cole BF, Mills P, Zuhowski EG, Saris S, Rhodes CH, Stopa E, Egorin MJ: Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14: 600-609, 1996
22. Brandes AA, Scelzi E, Salmistraro G, Ermani M, Carollo C, Berti F, Zampieri P, Baiocchi C, Friorentino MV: Incidence of risk of thromboembolism during treatment of high-grade gliomas: a prospective study. Eur J Cancer 33: 1592-1596, 1997
23. Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, Al-Sarraf M: The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 68: 2621-2624, 1991
24. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4: 121-133, 1993
25. Kornowski R, Pines A, Constantini S: Persistent activation of thrombocytes in neurosurgical patients operated for primary brain tumors. Acta Neurochir 121: 146-148, 1993
26. Hainsworth JD, Erland JB, Kalman LA, Schreeder MT, Greco FA: Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 15: 2385-2393, 1997
27. Bhattacharjee MB, Bruner JM: 11-6 p53 protein in pediatric malignant astrocytomas: a study of 21 patients. J Neuro-Oncol 32: 225-233, 1997
28. Kordek R, Biernat W, Alwasiak J, Maculewicz R, Yanagihara R, Liberski PP: p53 protein and epidermal growth factor receptor expression in human astrocytomas. J Neuro-Oncol 26: 11-16, 1995
29. Haas-Kogan DA, Yount G, Haas M, Levi D, Kogan SS, Hu L, Vidair C, Deen DF, Dewey WC, Israel MA: p53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. Int J Radiat Oncol Biol Phys 36: 95-103, 1996
30. Kondo S, Barnett GH, Hara H, Morimura T, Takeuchi J: MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis.Oncogene 18: 2001-2006, 1995
31. Pollack IF, Hamilton RL, Finkelstein SD, Campbell JW, Martinez AJ, Sherwin RN, Bozik ME, Gollin SM: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 57: 304-309,1997